Product Description
Dovitinib is a pan-tyrosine kinase inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR) and other receptor tyrosine kinases (RTKs). Allarity exclusively in-licensed it (globally) from Novartis, who had completed a Phase 3 study in renal cell carcinoma (RCC) in addition to several promising Phase 2 studies in breast, liver and endometrial cancer and GIST. (Sourced from: https://allarity.com/pipeline/dovitinib/)
Mechanisms of Action: RTK Inhibitor, FGFR Inhibitor, VEGF Inhibitor, KITl Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Renal Cell Carcinoma|Oncology Solid Tumor Unspecified
Phase 2: Glucagonoma|Gastrinoma|Islet Cell Adenoma|Pancreatic Cancer|Breast Cancer|Renal Cell Carcinoma|Non-Small-Cell Lung Cancer|Multiple Myeloma|Colorectal Cancer|Gastrointestinal Cancer|Neuroendocrine Carcinoma|Somatostatinoma|Insulinoma|Neuroendocrine Tumors|Melanoma|Gastrointestinal Stromal Tumors|Head and Neck Cancer|Thyroid Cancer|Adenoid Cystic Carcinoma|Islet Cell Carcinoma|Ovarian Cancer|Hepatocellular Carcinoma|Acute Myeloid Leukemia|Prostate Cancer|Inflammatory Breast Cancer|Mesothelioma|Adrenocortical Carcinoma|Endometrial Cancer|von Hippel-Lindau Disease|Transitional Cell Carcinoma|Gliosarcoma|Stomach Diseases|Salivary Gland Cancer|Scirrhous Adenocarcinoma|Pheochromocytoma|Paraganglioma|Glioblastoma|Brain Cancer|Linitis Plastica|Bladder Cancer|Oncology Unspecified|Kidney Cancer|Small Cell Lung Cancer|Oncology Solid Tumor Unspecified|Male Breast Cancer
Phase 1: Breast Cancer|Kidney Cancer|Renal Cell Carcinoma|Multiple Myeloma|Gastrointestinal Stromal Tumors|Oncology Solid Tumor Unspecified|Non-Small-Cell Lung Cancer|Thrombocytopenia|Pancreatic Cancer|Diarrhea|Adenocarcinoma|Glioblastoma|Acute Myeloid Leukemia|Bladder Cancer|Neutropenia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05571969 |
AL-2003 | P1 |
Suspended |
Neutropenia|Thrombocytopenia|Diarrhea |
2024-10-01 |
4% |
2025-02-05 |
Primary Endpoints |
ACTRN12620000921987p |
OPTIMISE-C19 | N/A |
Not yet recruiting |
COVID-19 |
2020-11-25 |
|||
NCT00831792 |
NCI-2011-01106 | P2 |
Completed |
Prostate Cancer |
2017-06-12 |
2019-03-18 |
Treatments |
|
NCT01994590 |
NCI-2014-00887 | P2 |
Terminated |
Prostate Cancer |
2017-06-05 |
2019-03-20 |
Treatments |
|
NCT01732107 |
GU12-157 | P2 |
Terminated |
Transitional Cell Carcinoma|Bladder Cancer |
2017-03-06 |
2019-03-22 |
||
JapicCTI-142557 |
JapicCTI-142557 | N/A |
Completed |
Oncology Solid Tumor Unspecified |
2017-03-01 |
|||
NCT02116803 |
CTKI258A2X01B | P3 |
Completed |
Oncology Solid Tumor Unspecified |
2016-11-28 |
2019-03-20 |
Treatments |
|
NCT01972750 |
TKI258 | P1 |
Unknown status |
Glioblastoma |
2016-11-01 |
2019-03-20 |
Treatments |
|
NCT02268435 |
AMC1401 | P1 |
Withdrawn |
Gastrointestinal Stromal Tumors |
2016-08-01 |
2019-03-20 |
Treatments |
|
NCT01921673 |
AMC1302 | P2 |
Completed |
Gastrointestinal Cancer |
2016-06-01 |
2019-03-19 |
Treatments |
|
2014-000368-17 |
2014-000368-17 | P2 |
Completed |
Oncology Solid Tumor Unspecified |
2016-04-07 |
2025-06-25 |
Treatments |
|
NCT01635907 |
UPCC 23811 | P2 |
Completed |
Pheochromocytoma|Paraganglioma |
2016-03-01 |
2023-03-30 |
Primary Endpoints|Treatments |
|
NCT01719549 |
GASDOVI-1 | P2 |
Completed |
Gastrointestinal Cancer |
2016-02-01 |
2019-03-19 |
Treatments |
|
NCT01676714 |
UCDCC#231 | P2 |
Completed |
Non-Small-Cell Lung Cancer|Colorectal Cancer |
2016-01-01 |
2019-03-19 |
Treatments |
|
NCT01831726 |
SIGNATURE | P2 |
Completed |
Ovarian Cancer|Gastrointestinal Cancer|Acute Myeloid Leukemia|Gastrointestinal Stromal Tumors|Thyroid Cancer|Head and Neck Cancer|Melanoma|Non-Small-Cell Lung Cancer |
2015-12-01 |
2019-03-19 |
Treatments |
|
NCT01266070 |
NCI-2011-00305 | P2 |
Terminated |
von Hippel-Lindau Disease |
2015-12-01 |
2019-03-19 |
Treatments |
|
NCT01484041 |
LCCC 2010-535 | P2 |
Terminated |
Breast Cancer |
2015-12-01 |
2019-03-19 |
Treatments |
|
NCT01262027 |
NCI-2011-00299 | P2 |
Completed |
Inflammatory Breast Cancer |
2015-11-25 |
2019-08-10 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT02048943 |
I 242513 | P1 |
Withdrawn |
Pancreatic Cancer|Adenocarcinoma |
2015-11-01 |
2019-03-20 |
Treatments |
|
NCT01678105 |
DOVE | P2 |
Completed |
Adenoid Cystic Carcinoma|Salivary Gland Cancer |
2015-09-01 |
2019-03-19 |
Treatments |
|
NCT01497392 |
I 175610 | P1 |
Completed |
Pancreatic Cancer|Adenocarcinoma |
2015-08-31 |
2024-06-26 |
Primary Endpoints|Treatments |
|
NCT01791387 |
DILIGENCE-1 | P2 |
Unknown status |
Renal Cell Carcinoma |
2015-06-01 |
2019-03-19 |
Treatments |
|
NCT01769547 |
DOVE-M | P2 |
Terminated |
Mesothelioma |
2015-06-01 |
2019-03-19 |
Treatments |
|
NCT02108782 |
RU021205I | P2 |
Withdrawn |
Pancreatic Cancer|Neuroendocrine Tumors|Somatostatinoma|Glucagonoma|Gastrinoma|Islet Cell Carcinoma|Neuroendocrine Carcinoma|Insulinoma|Islet Cell Adenoma |
2015-05-01 |
2019-03-22 |
Treatments |
|
2011-001230-42 |
2011-001230-42 | P2 |
Completed |
Breast Cancer |
2015-04-03 |
2022-03-13 |
Treatments |